Syquant Capital Sas Bio N Tech Se Transaction History
Syquant Capital Sas
- $70.5 Million
- Q4 2024
Shares
2 transactions
Others Institutions Holding BNTX
# of Institutions
364Shares Held
39.6MCall Options Held
3.01MPut Options Held
2.01M-
Baillie Gifford & CO8.22MShares$784 Million0.74% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.41MShares$420 Million2.03% of portfolio
-
Primecap Management CO Pasadena, CA4.3MShares$410 Million0.39% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$181 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$172 Million1.03% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $23.1B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...